Fig. 2

Sensorimotor improvements after PBMT. A, B EAE clinical score (A) and latency to fall in rotarod test (B) for EAE and EAE treated with PBMT (EAE-PBMT) animals. Time windows that were considered for analysis: baseline (D0–D11), onset of symptoms (D12–D16), peak of symptoms (D17–D21), and recovery stage (D22–D28). C Linear regression of the normalized latency to fall as a function of EAE clinical score. D Mouse posture at onset (top) and peak (bottom) of the symptoms with anatomical labels. E, F Top. Anatomical parameters of interest: tail tip height (E); sacrum height between tail base and iliac crest (F); limb elongation during locomotion period (G). Bottom, average evolution of the parameters of interest across the main stages of disease progression for untreated (gray) and PBMT-treated (red) mice. A–C n = 16 EAE and n = 12 EAE-PBMT mice. (E–G) n = 12 EAE and n = 8 EAE-PBMT mice. All the data were analyzed using the nonparametric two-tailed Mann–Whitney U test and presented as mean ± SEM; *P < 0.05; **P < 0.01; ***P < 0.001